Fibromyalgia (FM) is a chronic musculoskeletal pain syndrome that causes substantial physical and psychological impairment and costs over $25 billion annually. Current pharmacological therapies may be expensive, cause serious adverse effects, and fail to effectively improve pain and function. Thus, finding new and effective non-pharmacological treatments for FM patients is urgently needed. Previous research has demonstrated that Tai Chi, a traditional Chinese mind-body exercise, can improve both physical and mental health for FM patients. However, no clinical trials have demonstrated its clinical effectiveness compared to standard aerobic exercise therapy, or determined its optimum dose (frequency or duration) as a treatment for FM. We therefore propose to conduct the first comparative effectiveness trial of Tai Chi vs. aerobic exercise (a recommended component of the current standard of care) and to evaluate effectiveness under different Tai Chi dosing schedules in a large FM population.
We aim to (1) demonstrate that, compared to aerobic exercise, Tai Chi is a more effective intervention for managing the pain and improving the functional limitations that impact quality of life for FM patients, and 2) determine the optimal frequency and duration of a supervised Tai Chi intervention in relation to short and long-term effectiveness. To achieve this goal, we will conduct a single-blind, randomized controlled trial of Tai Chi vs. aerobic exercise in 216 patients who meet the American College of Rheumatology criteria for FM. Patients will be randomized to one of four Tai Chi intervention groups: 12 or 24 weeks of supervised Tai Chi given once or twice per week, or a supervised aerobic exercise control (2x/week for 24 weeks). All groups will have a 52-week follow-up. The primary outcome will be the FM Impact Questionnaire total score at 24 weeks. Secondary outcomes include the measures of widespread pain, functional performance, psychological functioning, self-efficacy, sleep quality, and quality of life at 12, 24, and 52 weeks. Successful completion of the proposed study will determine the ideal regimen of Tai Chi and demonstrate that Tai Chi can be a simple, effective, and durable treatment for this therapeutically challenging disorder. We believe that our work will convince the clinical community to implement Tai Chi as a first-line treatment for the millions of individuals with FM.
Fibromyalgia (FM) is the second most common rheumatologic condition in the United States and there are currently no satisfactory treatments. Innovative effective strategies are urgently needed. Tai Chi offers a novel and logistically feasible exercise regimen and a complementary mind-body approach to manage pain as well as enhance physical and mental health and wellness in patients with FM. Successful completion of the proposed study will demonstrate that Tai Chi is a simple, effective and durable treatment for FM. 1
|Kong, Jian; Wolcott, Emily; Wang, Zengjian et al. (2018) Altered resting state functional connectivity of the cognitive control network in fibromyalgia and the modulation effect of mind-body intervention. Brain Imaging Behav :|
|Seto, Andrew; Han, Xingyi; Price, Lori Lyn et al. (2018) The role of personality in patients with fibromyalgia. Clin Rheumatol :|
|Wang, Chenchen; Schmid, Christopher H; Fielding, Roger A et al. (2018) Effect of tai chi versus aerobic exercise for fibromyalgia: comparative effectiveness randomized controlled trial. BMJ 360:k851|
|Niles, Barbara L; Mori, DeAnna L; Polizzi, Craig P et al. (2016) Feasibility, qualitative findings and satisfaction of a brief Tai Chi mind-body programme for veterans with post-traumatic stress symptoms. BMJ Open 6:e012464|
|Wang, Chenchen; McAlindon, Timothy; Fielding, Roger A et al. (2015) A novel comparative effectiveness study of Tai Chi versus aerobic exercise for fibromyalgia: study protocol for a randomized controlled trial. Trials 16:34|
|Morgan, Nani; Irwin, Michael R; Chung, Mei et al. (2014) The effects of mind-body therapies on the immune system: meta-analysis. PLoS One 9:e100903|